Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319856 | 1.00 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL643984 | 1.00 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4476083 | 0.90 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL8950475 | 0.90 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4468251 | 0.90 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL21901972 | 0.82 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL25302148 | 0.81 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL9761279 | 0.81 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL23077378 | 0.81 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL12439955 | 0.81 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317416-A2 | 2-AMINO-2-ALKYL-4 HEXENOIC AND HEXYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | claimed |
| WO-2002022559-A2 | 2-AMINO-2-ALKYL-4 HEXENOIC AND HEXYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | claimed |
| JP-3227962-A | — | — | None | — | — | JP | disclosed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2022-11-15 | — | — | US | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| CN-110545814-A | Chemokine CXCR4 receptor modulators and uses related thereto | UNIV EMORY | 2019-12-06 | — | — | CN | disclosed |
| WO-2018156595-A1 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-2354136-B1 | NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME | INST PHARM & TOXICOLOGY AMMS (CN) | 2016-02-24 | — | — | EP | disclosed |
| EP-0641789-B1 | BENZOTHIADIAZINE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 1997-12-03 | — | — | EP | disclosed |
| US-5401739-A | Benzothiadiazine derivatives | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0641789-A1 | BENZOTHIADIAZINE DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0625978-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| JP-H03227962-A | PRODUCTION OF 4-AMINO-CIS-2-BUTEN-1-OL | IKEDA MOHANDOU:KK | 1991-10-08 | — | — | JP | disclosed |
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4489089-A | INHIBITION OF THE ENZYME THROMBOXANE SYNTHETASE | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0117462-A2 | N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides | AMERICAN CYANAMID COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CASP3 2722/4885CA12 3520/4885CA9 3149/4885 |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CASP3 2722/4885CA12 3520/4885CA9 3149/4885 |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCL12, CXCR1 | CASP3 2722/4885CA12 3520/4885CA9 3149/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | CASP3 2722/4885CA12 3520/4885CA9 3149/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | CASP3 2144/4885CA12 2293/4885CA9 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.